Inovio pharmaceuticals stock.

Inovio Pharmaceuticals (INO) Company Description: Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA ...

Inovio pharmaceuticals stock. Things To Know About Inovio pharmaceuticals stock.

Fast-forward 10 months, and it's clear that Inovio significantly lags behind peers such as Moderna, Pfizer, and AstraZeneca, who already have phase 3 clinical trials underway. Indeed, Inovio stock ...At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Inovio Pharmaceuticals Inc. If you are looking for stocks with good return, Inovio Pharmaceuticals Inc stock can be a bad, high-risk 1-year investment option.Data delayed at least 15 minutes, as of Nov 17 2023 07:01 GMT. More ▽. Find ...Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed 10 of the 11 (91%) patients saw a reduction in surgical interventions in the year following initial treatment New combined safety and immunological data showing tolerability and durable immune response presented at ABEA/COSM Announced positive data ...INO stock trades near $10 currently and it is, in fact, down 27% from its pre-Covid high of around $14 in early March 2020 – before the coronavirus pandemic hit the world. INO stock has had a ...Web

The latest price target for Inovio Pharmaceuticals ( NASDAQ: INO) was reported by RBC Capital on Thursday, May 11, 2023. The analyst firm set a price target for 2.00 expecting INO to rise to ...The consensus among analysts is that Inovio Pharmaceuticals Inc (INO) is a Hold stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 3 have rated it as a Hold, with 0 advising it as a Buy. 0 have rated the stock as Underweight.The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large fall of 17% over the last month ...

Inovio Pharmaceuticals. Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate ... 21 Sep 2020 ... ... Inovio Pharmaceuticals stock has run its course, and any significant upside from these levels is unlikely. INO stock has been very volatile ...

Oct. 10, 2023, 08:26 AM. (RTTNews) - Biotechnology company Inovio Pharmaceuticals, Inc. (INO) announced Tuesday that it has received feedback from the U.S. Food and Drug Administration (FDA) that ...WebNov 30, 2023 · Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA ... Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and …As of September 30, 2022, INOVIO had 249.5 million common shares outstanding and 268.7 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt. INOVIO reported ...

Inovio Pharmaceuticals, Inc. reports earnings ... In a free sample issue of our monthly newsletter we analyzed Warren Buffett’s stock picks covering the 1999-2017 period and identified the ...Web

Inovio Pharmaceuticals (INO) Q2 2023 Earnings Call Transcript finance.yahoo.com - August 9 at 9:04 PM: Inovio Pharmaceuticals cuts 30% of staff in third round of layoffs in 13 months bizjournals.com - August 1 at 7:38 PM: Inovio Pharmaceuticals (INO) Stock Up, Begins Recruitment for MERS Vaccine Trial thestreet.com - July 28 at 8:03 AM

Biotechnology firm Inovio Pharmaceuticals (INO) was one of the first companies to enter the race to release a Covid-19 vaccine, but delays have set back the process and it remains in the development stage. The company’s share price fell in late 2020, but it has gained 19 per cent so far this year, with the firm moving ahead with …The latest price target for Inovio Pharmaceuticals ( NASDAQ: INO) was reported by RBC Capital on Thursday, May 11, 2023. The analyst firm set a price target for 2.00 expecting INO to rise to ...1 Mei 2020 ... Inovio Pharmaceuticals' stock has climbed higher and higher over the past month since it said it was working on a speedy COVID-19 vaccine.A high-level overview of Inovio Pharmaceuticals, Inc. (INO) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.The average trading volume of INO on November 28, 2023 was 3.45M shares. INO) stock’s latest price update. Inovio Pharmaceuticals Inc (NASDAQ: INO)’s stock price has decreased by -3.07 compared to its previous closing price of 0.41. However, the company has seen a -5.38% decrease in its stock price over the last five trading sessions.52-week High/Low: $2.07 / $0.32. 50/200 Day Moving Average: $0.407 / $0.664. This figure corresponds to the Average Price over the previous 50/200 days. For Inovio Pharmaceuticals stocks, the 50-day moving average is the support level today. For Inovio Pharmaceuticals stocks, the 200-day moving average is the resistance level today.WebShares of Inovio Pharmaceuticals (INO 0.96%) ... There's also the worry the stock could be delisted from the Nasdaq Stock Market if it continues to trade below $1, which would make it more ...

Find out the direct holders, institutional holders and mutual fund holders for Inovio Pharmaceuticals, Inc. (INO).Data delayed at least 15 minutes, as of Nov 17 2023 07:01 GMT. More ▽. Find ...INO is the ticker symbol for Inovio Pharmaceuticals, Inc., a biotechnology company that develops and commercializes DNA medicines to treat and protect people from HPV-associated diseases, cancer, and infectious diseases. The web page shows its stock price, news, analysis, and performance outlook on NasdaqGS. INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program 10-10 - 1 view Inovio Pharmaceuticals, Inc. Stock Option Grant Notice (2023 Omnibus Incentive Plan) 08-09 - 1 view Inovio Pharmaceuticals, Inc. RSU Award Grant Notice (2023 Omnibus Incentive …WebInovio Pharmaceuticals Inc stock price live 0.3783, this page displays NASDAQ INO stock exchange data. View the INO premarket stock price ahead of the market session or assess the after hours quote.Research Inovio Pharmaceuticals' (Nasdaq:INO) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance ...

View the latest Inovio Pharmaceuticals Inc. (INO) stock price, news, historical charts, analyst ratings and financial information from WSJ.

While many coronavirus stocks soared to record highs over the past year, shares of Inovio Pharmaceuticals ( INO -5.75%) are down nearly 50% over the past 12 months. The company has not advanced ...WebIn a major shakeup at Inovio Pharmaceuticals, company co-founder J. Joseph Kim is out as CEO. ... In early morning trading, Inovio's stock was down more than 31% at $1.72 per share.Apr 4, 2023 · Shares of Inovio Pharmaceuticals ( INO -2.12%) were down more than 10% on Tuesday afternoon, falling to a 52-week low of $0.07036 a share at one point. The biotechnology company specializes in ... Investors, Inovio Get Final OK For $44M Deal In Stock Suit. A Pennsylvania federal judge on Wednesday approved a $44 million deal between biotechnology firm Inovio Pharmaceuticals Inc. and its ...Inovio (INO) delivered earnings and revenue surprises of 48.28% and 3,880%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?10 Okt 2023 ... Inovio Pharmaceuticals (INO) shares rise after FDA issued positive feedback on its plans to obtain marketing nod for lead asset against a ...As of June 30, 2022, Inovio had 247.5 million shares of common stock outstanding and 267.8 million shares of common stock outstanding on a fully diluted basis. Total operating expenses were $104.9M.Feb 28, 2023 · On March 1, Inovio Pharmaceuticals will release figures for the most recent quarter. Wall Street analysts predict losses per share of $0.168. Watch Inovio Pharmaceuticals stock price in real-time ...

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program 10-10 - 1 view Inovio Pharmaceuticals, Inc. Stock Option Grant Notice (2023 Omnibus Incentive Plan) 08-09 - 1 view Inovio Pharmaceuticals, Inc. RSU Award Grant Notice (2023 Omnibus Incentive …

Stock analysis for Inovio Pharmaceuticals Inc (INO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

What Happened : Inovio Pharmaceuticals reported quarterly losses of 22 cents per share which missed the analyst consensus estimate of a loss of 17 cents. The company also reported quarterly sales ...WebInovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher again on Wednesday after surging more than 40% on Tuesday after the FDA said it can use data from the completed Phase 1 ...Inovio acquired it as a phase 1 asset back in 2009 when it merged with VGX Pharmaceuticals. Back in 2017 when I wrote my first Inovio article , it was Inovio's lead asset in phase 3 development.The latest price target for Inovio Pharmaceuticals ( NASDAQ: INO) was reported by RBC Capital on Thursday, May 11, 2023. The analyst firm set a price target for 2.00 expecting INO to rise to ... View Inovio Pharmaceuticals, Inc INO investment & stock information. Get the latest Inovio Pharmaceuticals, Inc INO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Inovio Pharmaceuticals has a 52-week low of $0.32 and a 52-week high of $1.99. The stock has a 50 day moving average price of $0.41 and a 200 day moving …INO is the ticker symbol for Inovio Pharmaceuticals, Inc., a biotechnology company that develops and commercializes DNA medicines to treat and protect people from HPV-associated diseases, cancer, and infectious diseases. The web page shows its stock price, news, analysis, and performance outlook on NasdaqGS.Inovio Pharmaceuticals, Inc. Common Stock (INO) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time Key Data Bid Price and Ask Price The bid & ask refers to the price that an...Feb 28, 2023 · On March 1, Inovio Pharmaceuticals will release figures for the most recent quarter. Wall Street analysts predict losses per share of $0.168. Watch Inovio Pharmaceuticals stock price in real-time ...

Galectin Therapeutics Inc. 1.99. -0.13. -6.13%. Get Inovio Pharmaceuticals Inc (INO:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Overview Stock Screener Earnings Calendar Sectors Nasdaq | INO U.S.: Nasdaq Inovio Pharmaceuticals Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 22, 2023 7:33 p.m....On eToro, you can buy $INO or other stocks and pay ZERO commission! Follow Inovio Pharmaceuticals Inc share price and get more information. Terms apply.BLUE BELL, Pa., May 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M ...WebInstagram:https://instagram. jordan 12 flugamevanguard sandp 500 index fund admiralbest cryptocurrency exchange uknsflx BLUE BELL, Pa., May 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M ...WebThe stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large fall of 17% over the last month ... pkg quotetpg value ROBERT J. JUBA JR. “INOVIO’s team has extensive experience manufacturing DNA medicines and a proven track record of producing them at unprecedented speeds.”. “INOVIO’s CELLECTRA® intramuscular and intracellular smart devices have allowed us to deliver our optimized DNA plasmids directly into cells in the body to produce immune responses. According to the issued ratings of 1 analysts in the last year, the consensus rating for Inovio Pharmaceuticals stock is Hold based on the current 1 hold rating for INO. The average twelve-month price prediction for Inovio Pharmaceuticals is $2.00 with a high price target of $2.00 and a low price target of $2.00. what is a prop firm Inovio Pharmaceuticals Inc (NASDAQ: INO) Up 1.94%: This Is What Analysts Are Now Forecasting Stocks Register 6 days ago Inovio Pharmaceuticals (NASDAQ:INO) Coverage Initiated at StockNews.com EIN News Pharmaceuticals 11 days ago The 3 Most Undervalued Biotech Stocks to Buy: November 2023 InvestorPlace 17 days ago.WebThe three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.